Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study

Ähnliche Einträge

• In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
  von: Megumi Iwai, et al.
  Veröffentlicht: (2024)
• Concentration–QTc Modeling to Support Clinical Development of Fezolinetant
  von: Jace C. Nielsen, et al.
  Veröffentlicht: (2025)
• Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
  von: Megumi Iwai, et al.
  Veröffentlicht: (2025)
• Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
  von: Mary P. Choules, et al.
  Veröffentlicht: (2025)
• Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants
  von: Masaya Tachibana, et al.
  Veröffentlicht: (2025)